Skip to main content
SpringerLink
Log in

Somatostatin receptors and their interest in diagnostic pathology

  • Review
  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Since the discovery of somatostatin (SS) and of its interactions with a family of specific somatostatin receptors (sst), a wide body of evidence has been reported on its biological activities. Those activities include inhibition of hormone secretion, neuromodulatory properties in the central nervous system, cell growth control, and induction of apoptosis. At the same time, the distribution of sst has been analyzed in both normal and pathological tissues and sst subtype selective SS-analogs, able to mimic most SS functions, have been developed. The results have been fundamental insights into sst physiology and potent clinical implications in a variety of neoplastic and non neoplastic diseases. Neuroendocrine tumors have been particular targets of investigation. Alternative methods have been validated and are available to analyze the presence and functionality of sst at the level of either mRNA or protein. These methods include RT-PCR, Northern blot, in situ hybridization, immunohistochemistry, autoradiography, and in vivo scintigraphy. Tissue localization techniques are now accessible to many pathology laboratories worldwide and the role of the pathologist in typing the different sst present in a given sample is becoming more and more crucial. This is particularly, but not exclusively, the case in the field of neuroendocrine oncology, where sst typing may affect the clinical management of patients with sst-positive tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783–790, 1968.

    PubMed  CAS  Google Scholar 

  2. Epelbaum J. Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol 27:63–100, 1986.

    Article  PubMed  CAS  Google Scholar 

  3. Weir GC, Bonner-Weir S. Pancreatic somatostatin. Adv Exp Med Biol 188:403–423, 1985.

    PubMed  CAS  Google Scholar 

  4. Bloom SR, Mortimer CH, Thorner MO, et al. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet 2:1106–1109, 1974.

    Article  PubMed  CAS  Google Scholar 

  5. Bloom SR, Ralphs DN, Besser GM, et al. Proceedings: effect of somatostatin on motilin levels and gastric emptying. Gut 16:834, 1975.

    PubMed  CAS  Google Scholar 

  6. Raynor K, Lucki I, Reisine T. Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats. J Pharmacol Exp Ther 265:67–73, 1993.

    PubMed  CAS  Google Scholar 

  7. Haroutunian V, Mantin R, Campbell GA, Tsuboyama GK, Davis KL. Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res 403:234–242, 1987.

    Article  PubMed  CAS  Google Scholar 

  8. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450–482, 1991.

    PubMed  CAS  Google Scholar 

  9. Schonbrunn A, Tashjian H, Jr. Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 253:6473–6483, 1978.

    PubMed  CAS  Google Scholar 

  10. Raynor K, Reisine T. Somatostatin receptors. Crit Rev Neurobiol 6:273–289, 1992.

    PubMed  CAS  Google Scholar 

  11. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16:86–88, 1995.

    Article  PubMed  CAS  Google Scholar 

  12. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 20:348–367, 1997.

    PubMed  CAS  Google Scholar 

  13. Cole SL, Schindler M. Characterisation of somatostatin sst2 receptor splice variants. J Physiol Paris 94:217–237, 2000.

    Article  PubMed  CAS  Google Scholar 

  14. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 16:427–442, 1995.

    Article  PubMed  CAS  Google Scholar 

  15. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 57:1249–1265, 1995.

    Article  PubMed  CAS  Google Scholar 

  16. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 258:1952–1955, 1992.

    Article  PubMed  CAS  Google Scholar 

  17. Koch BD, Schonbrunn A. The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes. Endocrinology 114:1784–1790, 1984.

    PubMed  CAS  Google Scholar 

  18. Viguerie N, Tahiri-Jouti N, Ayral AM, et al. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism. Endocrinology 124:1017–1025, 1989.

    PubMed  CAS  Google Scholar 

  19. Schonbrunn A, Gu YZ, Dournard P, Beaudet A, Tannenbaum GS, Brown PJ. Somatostatin receptor subtypes: specific expression and signaling properties. Metabolism 45:8–11, 1996.

    Article  PubMed  CAS  Google Scholar 

  20. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 20:157–198, 1999.

    Article  PubMed  CAS  Google Scholar 

  21. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy 47:30–39, 2001.

    Article  PubMed  CAS  Google Scholar 

  22. Ferguson SS, Barak LS, Zhang J, Caron MG. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 74:1095–1110, 1996.

    Article  PubMed  CAS  Google Scholar 

  23. Rocheville M, Lange DC, Kumar U, et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862–7869, 2000.

    Article  PubMed  CAS  Google Scholar 

  24. Pfeiffer M, Koch T, Schroder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 2767:14027–14036, 2001.

    Google Scholar 

  25. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277:19762–19772, 2002.

    Article  PubMed  CAS  Google Scholar 

  26. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154–157, 2000.

    Article  PubMed  CAS  Google Scholar 

  27. Raynor K, Murphy WA, Coy DH, et al. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 43:838–844, 1993.

    PubMed  CAS  Google Scholar 

  28. de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 14:53–57, 2002.

    Article  PubMed  Google Scholar 

  29. Fukusumi S, Kitada C, Takekawa S, et al. Identification and characterization of a novel human cortistatin-like peptide. Biochem Biophys Res Commun 232:157–163, 1997.

    Article  PubMed  CAS  Google Scholar 

  30. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135:2814–2817, 1994.

    Article  PubMed  CAS  Google Scholar 

  31. Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism 45:17–20, 1996.

    Article  PubMed  CAS  Google Scholar 

  32. Lewis I, Bauer W, Albert R, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 46:2334–2344, 2003.

    Article  PubMed  CAS  Google Scholar 

  33. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12:S111–1114, 2001.

    Article  PubMed  Google Scholar 

  34. Sarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 47:1–29, 2001.

    Article  Google Scholar 

  35. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 79:830–834, 1997.

    Article  PubMed  CAS  Google Scholar 

  36. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731, 1993.

    Article  PubMed  CAS  Google Scholar 

  37. Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 131:577–581, 1994.

    PubMed  CAS  Google Scholar 

  38. Smith MC, Liu J, Chen T, et al. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 62:69–72, 2000.

    Article  PubMed  CAS  Google Scholar 

  39. de Jong M, Breeman WA, Bernard BF, et al. [177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92:628–633, 2001.

    Article  PubMed  Google Scholar 

  40. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 334:246–254, 1996.

    Article  PubMed  CAS  Google Scholar 

  41. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 9:417–436, 1988.

    PubMed  CAS  Google Scholar 

  42. Lamberts SW, Reubi JC, Uiterlinden P, Zuiderwijk J, van den Werff P, van Hal P. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology 118:2188–2194, 1986.

    PubMed  CAS  Google Scholar 

  43. Siegel RA, Tolcsvai L, Rudin M. Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). Cancer Res 48:4651–4655, 1988.

    PubMed  CAS  Google Scholar 

  44. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28–47, 2003.

    Article  PubMed  CAS  Google Scholar 

  45. Koper JW, Hofland LJ, van Koetsveld PM, den Holder F, Lamberts SW. Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. Cancer Res 50:6238–6242, 1990.

    PubMed  CAS  Google Scholar 

  46. Mahy N, Woolkalis M, Manning D, Reisine T. Characteristics of somatostatin desensitization in the pituitary tumor cell line AtT-20. J Pharmacol Exp Ther 247:390–396, 1988.

    PubMed  CAS  Google Scholar 

  47. Srikant CB, Heisler S. Relationship between receptor binding and biopotency of somatostatin-14 and somatostatin-28 in mouse pituitary tumor cells. Endocrinology 117:271–278, 1985.

    PubMed  CAS  Google Scholar 

  48. Elberg G, Hipkin RW, Schonbrunn A. Homologous and heterologous regulation of somatostatin receptor 2. Mol Endocrinol 16:2502–2514, 2002.

    Article  PubMed  CAS  Google Scholar 

  49. Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 110:1147–1154, 1982.

    PubMed  CAS  Google Scholar 

  50. Visser-Wisselaar HA, Van Uffelen CJ, Van Koetsveld PM, et al. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology 138:1180–1189, 1997.

    Article  PubMed  CAS  Google Scholar 

  51. Kimura N, Hayafuji C, Konagaya H, Takahashi K. 17 beta-estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. Endocrinology 119:1028–1036, 1986.

    Article  PubMed  CAS  Google Scholar 

  52. James RA, Sarapura VD, Bruns C, et al. Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor. Endocrinology 138:719–724, 1997.

    Article  PubMed  CAS  Google Scholar 

  53. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43:27–35, 1992.

    Article  PubMed  CAS  Google Scholar 

  54. Zhang CY, Yokogoshi Y, Yoshimoto K, Fujinaka Y, Matsumoto K, Saito S. Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 210:805–815, 1995.

    Article  PubMed  CAS  Google Scholar 

  55. Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86:3809–3814, 2001.

    Article  PubMed  CAS  Google Scholar 

  56. Lamberts SW, Hofland LJ, van Koetsveld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 71:566–574, 1990.

    PubMed  CAS  Google Scholar 

  57. Papotti M, Macri L, Bussolati G, Reubi JC. Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer 43:365–369, 1989.

    Article  PubMed  CAS  Google Scholar 

  58. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG, Lamberts SW. Somatostatin receptors in human endocrine tumors. Cancer Res 47:551–558, 1987.

    PubMed  CAS  Google Scholar 

  59. Kong H, DePaoli AM, Breder CD, Yasuda K, Bell GI, Reisine T. Differential expression of messenger RNAs for somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brain: analysis by RNA blotting and in situ hybridization histochemistry. Neuroscience 59:175–184, 1994.

    Article  PubMed  CAS  Google Scholar 

  60. Janson ET, Gobl A, Kalkner KM, Oberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56:2561–2565, 1996.

    PubMed  CAS  Google Scholar 

  61. Reubi JC, Schacr JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455–3459, 1994.

    PubMed  CAS  Google Scholar 

  62. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 70:530–537, 1997.

    Article  PubMed  CAS  Google Scholar 

  63. Papotti M, Croce S, Macri L, et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 9:47–57, 2000.

    Article  PubMed  CAS  Google Scholar 

  64. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 439:787–797, 2001.

    PubMed  CAS  Google Scholar 

  65. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461–475, 2002.

    Article  PubMed  CAS  Google Scholar 

  66. Sestini R, Orlando C, Peri A, et al. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res 2:1757–1765, 1996.

    PubMed  CAS  Google Scholar 

  67. Helboe L, Moller M, Norregaard L, Schiodt M, Stidsen CE. Development of selective antibodies against the human somatostatin receptor subtypes sst1–sst5. Brain Res Mol Brain Res 49:82–88, 1997.

    Article  PubMed  CAS  Google Scholar 

  68. Hofland LJ, Liu Q, Van Koetsveld PM, et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 84:775–780, 1999.

    Article  PubMed  CAS  Google Scholar 

  69. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 58:2375–2378, 1998.

    PubMed  CAS  Google Scholar 

  70. Kumar U, Laird D, Srikant CB, Escher E, Patel YC. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138:4473–4476, 1997.

    Article  PubMed  CAS  Google Scholar 

  71. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 153:233–245, 1998.

    PubMed  CAS  Google Scholar 

  72. Schindler M, Sellers LA, Humphrey PP, Emson PC. Immunohistochemical localization of the somatostatin SST2(A) receptor in the rat brain and spinal cord. Neuroscience 76:225–240, 1997.

    Article  PubMed  CAS  Google Scholar 

  73. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54:641–649, 2001.

    Article  CAS  Google Scholar 

  74. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50:52–60, 2002.

    Article  PubMed  CAS  Google Scholar 

  75. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 85:3882–3891, 2000.

    Article  PubMed  CAS  Google Scholar 

  76. Bruno JF, Xu Y, Song J, Berelowitz M. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 133:2561–2567, 1993.

    Article  PubMed  CAS  Google Scholar 

  77. Breder CD, Yamada Y, Yasuda K, Seino S, Saper CB, Bell GI. Differential expression of somatostatin receptor subtypes in brain. J Neurosci 12:3920–3934, 1992.

    PubMed  CAS  Google Scholar 

  78. Kong H, DePaoli AM, Breder CD, Yasuda K, Bell GI, Reisine T. Differential expression of messenger RNAs for somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brain: analysis by RNA blotting and in situ hybridization histochemistry. Neuroscience 59:175–184, 1994.

    Article  PubMed  CAS  Google Scholar 

  79. Thoss VS, Perez J, Duc D, Hoyer D. Embryonic and postnatal mRNA distribution of five somatostatin receptor subtypes in the rat brain. Neuropharmacology 34:1673–1688, 1995.

    Article  PubMed  CAS  Google Scholar 

  80. Thoss VS, Perez J, Probst A, Hoyer D. Expression of five somatostatin receptor mRNAs in the human brain and pituitary. Naunyn Schmiedebergs Arch Pharmacol 354:411–419, 1996.

    Article  PubMed  CAS  Google Scholar 

  81. Dournaud P, Gu YZ, Schonbrunn A, Mazella J, Tannenbaum GS, Beaudet A. Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody. J Neurosci 16:4468–4478, 1996.

    PubMed  CAS  Google Scholar 

  82. Day R, Dong W, Panetta R, Kraicer J, Greenwood MT, Patel YC. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology 136:5232–5235, 1995.

    Article  PubMed  CAS  Google Scholar 

  83. O’Carroll AM, Krempels K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endocrinology 136:5224–5227, 1995.

    Article  PubMed  CAS  Google Scholar 

  84. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56:333–342, 1995.

    Article  PubMed  CAS  Google Scholar 

  85. Hunyady B, Hipkin RW, Schonbrunn A, Mezey E. Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. Endocrinology 138:2632–2635, 1997.

    Article  Google Scholar 

  86. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48:77–85, 1999.

    Article  PubMed  CAS  Google Scholar 

  87. Mitra SW, Mezey E, Hunyady B, et al. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 140:3790–3796, 1999.

    Article  PubMed  CAS  Google Scholar 

  88. Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol 8:126–132, 2000.

    Article  PubMed  CAS  Google Scholar 

  89. Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111–117, 2000.

    Article  PubMed  CAS  Google Scholar 

  90. Reubi JC, Krenning E, Lamberts SW, Kvols L. In vitro detection of somatostatin receptors in human tumors. Metabolism 41:104–110, 1992.

    Article  PubMed  CAS  Google Scholar 

  91. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann NY Acad Sci 733:122–137, 1994.

    Article  PubMed  CAS  Google Scholar 

  92. Reubi JC, Schaer JC, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45:39–41, 1996.

    Article  PubMed  CAS  Google Scholar 

  93. Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 20:265–269, 2003.

    Article  PubMed  CAS  Google Scholar 

  94. Briganti V, Sestini R, Orlando C, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 3:2385–2391, 1997.

    PubMed  CAS  Google Scholar 

  95. Guitera-Rovel P, Lumbroso J, Gautier-Gougis MS, et al. Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol 12:807–811, 2001.

    Article  PubMed  CAS  Google Scholar 

  96. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80:2974–2979, 1995.

    Article  PubMed  CAS  Google Scholar 

  97. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724–729, 1994.

    Article  PubMed  CAS  Google Scholar 

  98. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398–403, 1994.

    Article  PubMed  CAS  Google Scholar 

  99. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201–995 in treatment of human endocrine tumors. J Clin Invest 93:1321–1325, 1994.

    Article  PubMed  CAS  Google Scholar 

  100. Epelbaum J, Bertherat J, Prevost G, et al. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 80:1837–1844, 1995.

    Article  PubMed  CAS  Google Scholar 

  101. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386–1392, 1995.

    Article  PubMed  CAS  Google Scholar 

  102. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 5:3483–3487, 1999.

    PubMed  CAS  Google Scholar 

  103. Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol 12:S31–36, 2001.

    Article  PubMed  Google Scholar 

  104. Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A. Immunohistochemical detection of somatostatin receptor subtypes in “clinically nonfunctioning” pituitary adenomas. Endocr Pathol 14:231–8, 2003.

    PubMed  CAS  Google Scholar 

  105. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 14:38–45, 2002.

    Article  PubMed  CAS  Google Scholar 

  106. Arnold R, Wied M, Behr TH. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 3:643–656, 2002.

    Article  PubMed  CAS  Google Scholar 

  107. Berenger N, Moretti JL, Boaziz C, Vigneron N, Morere JF, Breau JL. Somatostatin receptor imaging in small cell lung cancer. Eur J Cancer 32:1429–1431, 1996.

    Article  Google Scholar 

  108. Bombardieri E, Crippa F, Cataldo I, et al. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. Eur J Cancer 31:184–188, 1995.

    Article  Google Scholar 

  109. O’Byrne KJ, Halmos G, Pinski J, et al. Somatostatin receptor expression in lung cancer. Eur J Cancer 30:1682–1687, 1994.

    Article  Google Scholar 

  110. Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 39:224–227, 1998.

    PubMed  CAS  Google Scholar 

  111. Vaccarili M, Lococo A, Fabiani F, Staffilano A. Clinical diagnostic application of 111In-DTPA-octreotide scintigraphy in small cell lung cancer. Tumori 86:224–228, 2000.

    PubMed  CAS  Google Scholar 

  112. Reubi JC, Waser B, Sheppard M, Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 45:269–274, 1990.

    Article  PubMed  CAS  Google Scholar 

  113. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64:567–573, 1991.

    PubMed  CAS  Google Scholar 

  114. Kwekkeboom DJ, Reubi JC, Lamberts SW, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413–1417, 1993.

    Article  PubMed  CAS  Google Scholar 

  115. Tisell LE, Ahlman H, Wangberg B, et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 84:543–547, 1997.

    Article  PubMed  CAS  Google Scholar 

  116. Mato E, Matias-Guiu X, Chico A, et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab 83:2417–2420, 1998.

    Article  PubMed  CAS  Google Scholar 

  117. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera A. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol 95:300–308, 1991.

    PubMed  CAS  Google Scholar 

  118. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282, 2000.

    Article  PubMed  CAS  Google Scholar 

  119. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 29:855–862, 2002.

    Article  PubMed  CAS  Google Scholar 

  120. Pilichowska M, Kimura N, Suzuki A, Yoshida R, Schindler M, Nagura H. Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma. Endocr Pathol 12:55–61, 2001.

    Article  PubMed  CAS  Google Scholar 

  121. Alberini JL, Meunier B, Denzler B, et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat 61:21–32, 2000.

    Article  PubMed  CAS  Google Scholar 

  122. Zhao B, Zhao H, Zhao N, Zhu XG. Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment. J Hepatobiliary Pancreat Surg 9:497–502, 2002.

    Article  PubMed  Google Scholar 

  123. Pilichowska M, Kimura N, Schindler M, Kobari M. Somatostatin type 2A receptor immunoreactivity in human pancreatic adenocarcinomas. Endocr Pathol 12:147–155, 2001.

    Article  PubMed  CAS  Google Scholar 

  124. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49:1245–1250, 2002.

    PubMed  CAS  Google Scholar 

  125. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–447, 1998.

    Article  PubMed  CAS  Google Scholar 

  126. Laws SA, Gough AC, Evans AA, Bains MA, Primrose JN. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br J Cancer 75:360–366, 1997.

    PubMed  CAS  Google Scholar 

  127. Vuaroqueaux V, Dutour A, Bourhim N, et al. Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma. J Mol Endocrinol 24:397–408, 2000.

    Article  PubMed  CAS  Google Scholar 

  128. Hall GH, Turnbull LW, Richmond I, Helboe L, Atkin SL. Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. Br J Cancer 87:86–90, 2002.

    Article  PubMed  CAS  Google Scholar 

  129. Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 24:415–422, 2001.

    PubMed  CAS  Google Scholar 

  130. Wang CH, Tang CW, Liu CL, Tang LP. Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 9:1904–1908, 2003.

    PubMed  CAS  Google Scholar 

  131. Guillermet J, Saint-Laurent N, Rochaix P, et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 100:155–160, 2003.

    Article  PubMed  CAS  Google Scholar 

  132. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, Susini C, Buscail L. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 62:6124–6131, 2002.

    PubMed  CAS  Google Scholar 

  133. Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 60:2996–3001, 2000.

    PubMed  CAS  Google Scholar 

  134. Sulkowski U, Dinse P, Haus U, Collins W. Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months. Digestion 58:407–409, 1997.

    Article  PubMed  CAS  Google Scholar 

  135. Dizeyi N, Konrad L, Bjartell A, et al. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 7:91–98, 2002.

    Article  PubMed  CAS  Google Scholar 

  136. Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 53:50–59, 2002.

    Article  PubMed  CAS  Google Scholar 

  137. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836–846, 2001.

    Article  PubMed  CAS  Google Scholar 

  138. Sinisi AA, Bellastella A, Prezioso D, et al. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. J Clin Endocrinol Metab 82:2566–2569, 1997.

    Article  PubMed  CAS  Google Scholar 

  139. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 80:2806–2814, 1995.

    Article  PubMed  CAS  Google Scholar 

  140. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 85:2564–2571, 2000.

    Article  PubMed  CAS  Google Scholar 

  141. Vainas IG. Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy 47:109–126, 2001.

    Article  PubMed  CAS  Google Scholar 

  142. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 59:1947–1953, 1999.

    PubMed  CAS  Google Scholar 

  143. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100:393–398, 1993.

    Article  PubMed  CAS  Google Scholar 

  144. Guate JL, Escaf S, Menendez CL, del Valle M, Vega JA. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. Urol Int 59:149–153, 1997.

    Article  PubMed  CAS  Google Scholar 

  145. Ardjomand N, Ardjomand N, Schaffler G, Radner H, El-Shabrawi Y. Expression of somatostatin receptors in uveal melanomas. Invest Ophthalmol Vis Sci 44:980–987, 2003.

    Article  PubMed  Google Scholar 

  146. Lum SS, Fletcher WS, O’Dorisio MS, Nance RW, Pommier RF, Caprara M. Distribution and functional significance of somatostatin receptors in malignant melanoma. World J Surg 25:407–412, 2001.

    Article  PubMed  CAS  Google Scholar 

  147. Florio T, Montella L, Corsaro A, et al. In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Res 23:2465–2471, 2003.

    PubMed  CAS  Google Scholar 

  148. Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer 86:1621–1627, 1999.

    Article  PubMed  CAS  Google Scholar 

  149. Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi’s sarcoma tumor growth through inhibition of angiogenesis. FASEB J 13:647–655, 1999.

    PubMed  CAS  Google Scholar 

  150. Dutour A, Kumar U, Panetta R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76:620–627, 1998.

    Article  PubMed  CAS  Google Scholar 

  151. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 47:5758–5764, 1987.

    PubMed  CAS  Google Scholar 

  152. Reubi JC, Maurer R, Klijn JG, et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 63:433–438, 1986.

    Article  PubMed  CAS  Google Scholar 

  153. Ferone D, Hofland LJ, Colao A, Lamberts SW, van Hagen PM. Neuroendocrine aspects of immunolymphoproliferative diseases. Ann Oncol 12:S125–130, 2001.

    Article  PubMed  Google Scholar 

  154. van den Anker-Lugtenburg PJ, Lowenberg B, Lamberts SW, Krenning EP. The relevance of somatostatin receptor expression in malignant lymphomas. Metabolism 45:96–97, 1996.

    Article  PubMed  Google Scholar 

  155. Goldsmith SJ, Macapinlac HA, O’Brien JP. Somatostatin-receptor imaging in lymphoma. Semin Nucl Med 25:262–271, 1995.

    Article  PubMed  CAS  Google Scholar 

  156. Lugtenburg PJ, Krenning EP, Valkema R, et al. Somatostatin receptor scintigraphy useful in stage I–II Hodgkin’s disease: more extended disease identified. Br J Haematol 112:936–944, 2001.

    Article  PubMed  CAS  Google Scholar 

  157. Lugtenburg PJ, Lowenberg B, Valkema R, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin’s lymphomas. J Nucl Med 42:222–229, 2001.

    PubMed  CAS  Google Scholar 

  158. Ferone D, Kwekkeboom DJ, Pivonello R. et al. In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. J Endocrinol Invest 24:522–528, 2001.

    PubMed  CAS  Google Scholar 

  159. Marienhagen J, Schalke B, Aebert H, Held P, Eilles C, Bogdahn U. Somatostatin receptor scintigraphy in thymoma imaging method and clinical application. Pathol Res Pract 195:575–581, 1999.

    PubMed  CAS  Google Scholar 

  160. Lastoria S, Vergara E, Palmieri G, et al. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phel-octreotide scintigraphy. J Nucl Med 39:634–639, 1998.

    PubMed  CAS  Google Scholar 

  161. Ferone D, van Hagen MP, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 85:1719–1726, 2000.

    Article  PubMed  CAS  Google Scholar 

  162. Pawlikowski M, Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuroendocrinol Lett 24:21–27, 2003.

    PubMed  CAS  Google Scholar 

  163. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res 33:295–299, 2001.

    Article  PubMed  CAS  Google Scholar 

  164. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57:425–441, 2002.

    Article  CAS  Google Scholar 

  165. Thermos K. Functional mapping of somatostatin receptors in the retina: a review. Vision Res 43:1805–1815, 2003.

    Article  PubMed  CAS  Google Scholar 

  166. Klisovic DD, O’Dorisio MS, Katz SE, et al. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci 42:2193–2201, 2001.

    PubMed  CAS  Google Scholar 

  167. van Hagen PM, Baarsma GS, Mooy CM, et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143:S43–51, 2000.

    Article  PubMed  Google Scholar 

  168. Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 42:21–26, 2001.

    PubMed  CAS  Google Scholar 

  169. Zavros Y, Rathinavclu S, Kao JY, et al. Treatment of Helicobacter gastritis with IL-4 requires somatostatin. Proc Natl Acad Sci USA 100:12944–12949, 2003.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences & Oncology, San Luigi Hospital, Orbassano, University of Turin, Turin, Italy

    Marco Volante MD

  2. Department of Biological and Clinical Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano (TO), Italy

    Francesca Bozzalla-Cassione &  Mauro Papotti MD

Authors
  1. Marco Volante MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Bozzalla-Cassione
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mauro Papotti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mauro Papotti MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volante, M., Bozzalla-Cassione, F. & Papotti, M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol 15, 275–291 (2004). https://doi.org/10.1385/EP:15:4:275

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/EP:15:4:275

Key Words

Search

Navigation